Litigation Details for Braintree Laboratories, Inc. v. Novel Laboratories, Inc. (Fed. Cir. 2015)

Braintree Laboratories, Inc. v. Novel Laboratories, Inc. (Fed. Cir. 2015)

Docket	15-1700	Date Filed	2015-06-04
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	6,946,149
Link to Docket	External link to docket

Details for Braintree Laboratories, Inc. v. Novel Laboratories, Inc. (Fed. Cir. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-04				External link to document
2015-06-04	33		claims 19, 20, and 23, of U.S. Patent No. 6,946,149 (“the ’149 patent”), which claims bowel-cleansing… of Appeals, as to U.S. Patent Number 6,946,149 (the '" 149 Patent"), and the Court having…CERTIFICATE (6907th) United States Patent (IO> Number: US 6~946,149 Cl Cleveland … 1213- 12 15. and 1597-1598.* Patent No.: 6,946,149 Issued: Sep. 20, 2005 …..................... A00000004-A00000029 US 6,946,149...............................................	External link to document

Braintree Laboratories v. Novel Laboratories, 15-1700: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Braintree Laboratories prevailed in the Federal Circuit dispute over Novel Laboratories’ proposed generic version of SUPREP Bowel Prep Kit. The Federal Circuit affirmed the district court’s determination that Braintree’s U.S. Patent No. 6,946,149 was not invalid for obviousness. The decision preserved patent protection for Braintree’s low-volume oral sulfate colon-cleansing method and blocked Novel’s Paragraph IV challenge during the remaining patent term. Braintree Labs., Inc. v. Novel Labs., Inc., 874 F.3d 1346 (Fed. Cir. 2017).

What was Braintree Laboratories v. Novel Laboratories about?

The case was a Hatch-Waxman patent infringement action involving SUPREP, an oral prescription bowel-preparation product used before colonoscopy.

Braintree marketed SUPREP under FDA New Drug Application No. 021892. Novel filed an abbreviated new drug application seeking approval to market a generic oral sulfate solution. Novel’s ANDA included a Paragraph IV certification asserting that Braintree’s patent was invalid, unenforceable, or not infringed.

Braintree sued Novel under 35 U.S.C. § 271(e)(2), alleging that the filing of Novel’s ANDA constituted an artificial act of patent infringement.

Item	Detail
Plaintiff	Braintree Laboratories, Inc.
Defendant	Novel Laboratories, Inc.
Federal Circuit docket	No. 15-1700
Federal Circuit decision	874 F.3d 1346
Product	SUPREP Bowel Prep Kit
Active ingredients	Sodium sulfate, potassium sulfate, and magnesium sulfate
Patent at issue	U.S. Patent No. 6,946,149
Technology	Low-volume oral sulfate solution for colon cleansing
Litigation pathway	Hatch-Waxman ANDA litigation
Core issue on appeal	Obviousness under 35 U.S.C. § 103

The case did not involve a biologic, biosimilar application, Orange Book-listed formulation patent litigation involving multiple patents, or a patent-license dispute.

What patent protected SUPREP in the Novel Laboratories litigation?

The central patent was U.S. Patent No. 6,946,149, titled “Oral Sulfate Solutions for Colon Cleansing.” The patent covered methods using an aqueous solution containing sodium sulfate, potassium sulfate, and magnesium sulfate to cleanse a patient’s colon.

The claimed technology addressed a commercial problem in bowel preparation: reducing the volume of liquid a patient must consume while achieving adequate cleansing. Earlier bowel-preparation products commonly required substantially larger fluid volumes or used different active ingredients.

The patent’s method claims focused on the combination of:

1. An aqueous solution containing the three sulfate salts;
2. Oral administration to a patient;
3. Use for colon cleansing before a medical procedure; and
4. A dosing regimen involving separated administrations.

The patent was important because it covered the clinical use of the sulfate-salt combination rather than merely claiming a chemical compound in isolation.

Patent and FDA product data

Category	Information
Patent	U.S. Patent No. 6,946,149
Patent title	Oral Sulfate Solutions for Colon Cleansing
Patent owner in litigation	Braintree Laboratories
FDA product	SUPREP Bowel Prep Kit
NDA	021892
Regulatory sponsor	Braintree Laboratories
Dosage form	Oral solution concentrate diluted before administration
Therapeutic use	Cleansing of the colon before colonoscopy

The asserted patent claims were method-of-use claims. That distinction mattered because Novel’s ANDA product was designed to be used for the same colon-cleansing indication, creating direct infringement exposure if the patent was valid and enforceable.

What did the district court decide?

The district court rejected Novel’s obviousness challenge and upheld the asserted claims of the ’149 patent. The court found that Novel had not established by clear and convincing evidence that the claimed method would have been obvious to a person of ordinary skill in the art.

The district court considered prior art relating to:

• High-volume polyethylene glycol bowel-preparation solutions;
• Sodium phosphate bowel-preparation products;
• Sulfate-based compositions;
• Electrolyte balance and patient safety;
• Osmolality and fluid-shift concerns; and
• Split-dose or repeated-dose administration.

Novel argued that the asserted claims simply combined known sulfate salts with known bowel-cleansing techniques. Braintree responded that the prior art did not provide a sufficient reason to select the claimed sulfate combination and dosing approach, particularly in view of safety concerns associated with highly concentrated or hyperosmotic solutions.

The district court credited Braintree’s evidence that a skilled artisan would have had concerns about electrolyte disturbances, fluid shifts, tolerability, and the clinical performance of a low-volume sulfate solution.

How did the Federal Circuit rule in Braintree v. Novel?

The Federal Circuit affirmed the district court’s decision. It held that the district court did not clearly err in finding that the asserted claims were not obvious.

The appellate court accepted the district court’s conclusion that the prior art did not establish an adequate motivation to combine the relevant teachings with a reasonable expectation of success.

The Federal Circuit’s analysis focused on the difference between identifying each claim element somewhere in the prior art and proving that a skilled artisan would have combined those elements in the claimed manner. Novel showed that individual components and general bowel-cleansing concepts were known. The court held that this evidence did not, by itself, establish obviousness.

The Federal Circuit also treated the technical risks associated with sulfate solutions as relevant to the reasonable-expectation-of-success inquiry. The prior art raised concerns about:

• Excessive osmotic activity;
• Electrolyte imbalance;
• Dehydration;
• Renal complications;
• Patient tolerability; and
• Whether the claimed formulation would provide effective cleansing at a reduced liquid volume.

The court therefore rejected a hindsight-based reconstruction of the invention.

Federal Circuit holding

The Federal Circuit held that:

• The asserted claims were not shown to be obvious;
• The district court applied the correct legal framework;
• The factual findings concerning motivation to combine were not clearly erroneous; and
• Braintree’s patent remained enforceable against Novel’s ANDA challenge.

The Federal Circuit did not establish that every low-volume sulfate bowel-preparation product would infringe the patent. Its decision was tied to the specific ANDA and asserted claims at issue.

Why did the court reject Novel’s obviousness challenge?

The case illustrates the importance of the motivation-to-combine and reasonable-expectation-of-success requirements in pharmaceutical obviousness litigation.

The prior art disclosed components, but not the complete clinical solution

Novel relied on references that disclosed sulfate salts, bowel cleansing, and alternative preparation regimens. The Federal Circuit accepted that these references supplied substantial information, but it did not treat the claim as a simple aggregation of known elements.

The claimed method required a technically workable combination that achieved effective colon cleansing with a lower-volume regimen. The court required evidence that a skilled artisan would have pursued that combination and reasonably expected it to succeed.

The prior art contained safety concerns

The prior art did not present sulfate solutions as an uncomplicated substitute for existing bowel-preparation products. Concerns about hyperosmolarity, fluid shifts, electrolyte abnormalities, and patient safety made the claimed formulation less predictable.

Those concerns weakened Novel’s argument that routine optimization would have led directly to the claimed method.

Commercial success supported nonobviousness

Braintree presented evidence concerning SUPREP’s commercial performance and market acceptance. The Federal Circuit treated the commercial evidence as consistent with the nonobviousness finding, although the decision did not make commercial success independently dispositive.

For pharmaceutical patents, commercial success has greater evidentiary value when the patented features are tied to the product’s market performance. The relevant inquiry is whether the success resulted from the claimed technology rather than from unrelated factors such as marketing, brand reputation, or regulatory exclusivity.

What was the Paragraph IV challenge in this case?

Novel’s ANDA included a Paragraph IV certification. Under the Hatch-Waxman framework, that certification asserted that the relevant Braintree patent was invalid, unenforceable, or would not be infringed by Novel’s proposed generic product.

Braintree’s infringement suit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the governing procedural events in the case.

The litigation converted Novel’s regulatory filing into an immediate patent dispute. Novel could not wait for commercial launch and then defend a conventional infringement action. The ANDA filing itself supplied the jurisdictional basis for Braintree’s suit.

The Federal Circuit’s affirmance removed Novel’s principal invalidity position on appeal. Because the decision upheld the patent, Novel faced continued barriers to approval and commercial launch for the accused product during the applicable patent term.

What was the Orange Book status of SUPREP?

SUPREP was approved as an NDA product and was associated with an Orange Book-listed patent. The ’149 patent was the central patent asserted in the Novel litigation.

The Orange Book listing was commercially significant because it enabled Braintree to invoke Hatch-Waxman litigation after receiving Novel’s Paragraph IV certification. An NDA sponsor’s ability to list an eligible patent can delay generic approval through the statutory stay and create settlement leverage.

Orange Book listing does not itself establish that a patent is valid or infringed. The Braintree litigation illustrates the distinction:

• The FDA determines regulatory approval and therapeutic equivalence issues.
• The courts determine patent validity, enforceability, and infringement.
• A Paragraph IV certification creates a patent dispute but does not invalidate the listed patent.
• A favorable patent judgment can delay generic entry even after the generic sponsor has completed substantial FDA development work.

When did Braintree’s SUPREP patent lose exclusivity?

The ’149 patent was an issued U.S. patent with a term governed principally by the modern 20-year patent-term framework, subject to any applicable patent-term adjustment or extension. The litigation record and Federal Circuit decision concern the patent’s validity, not a new regulatory exclusivity period.

SUPREP’s market protection had several separate components:

Exclusivity type	Relevance
Patent exclusivity	Based on the term of the ’149 patent and any applicable adjustments
NDA regulatory exclusivity	Separate from patent protection and governed by FDA rules
Orange Book listing	Enabled the Hatch-Waxman patent-challenge process
Clinical-use protection	Reflected in the method-of-use patent claims
Brand commercial protection	Depended on physician adoption, formulation, and market access

Patent expiration does not automatically eliminate all regulatory or commercial barriers. Conversely, FDA approval of a generic does not determine whether the generic product infringes a valid patent outside the scope of the ANDA litigation.

Did Braintree v. Novel involve formulation patents or method-of-use patents?

The ’149 patent was principally a method-of-use patent. It protected the use of a sulfate-containing oral solution for colon cleansing under specified administration conditions.

The distinction is commercially relevant:

• A formulation patent generally protects the composition, concentration, dosage form, excipient system, or manufacturing process.
• A method-of-use patent protects administration of a product for a specified therapeutic purpose.
• An ANDA sponsor may attempt a section viii “carve-out” for a patented indication, but that strategy is difficult when the patented use corresponds to the product’s principal approved use.
• A method-of-use patent can create substantial launch risk when the generic product label instructs the same use claimed in the patent.

The case did not establish a broad monopoly over all bowel-preparation formulations or all sulfate-containing compositions. Its protection depended on the claim language and the accused product’s proposed use.

What was the litigation outcome and generic launch risk?

The Federal Circuit’s 2017 decision preserved Braintree’s favorable judgment. Novel did not obtain reversal on obviousness, and the appellate decision maintained the patent barrier against the accused ANDA product.

Risk category	Effect of the decision
Invalidity risk	Reduced for the asserted claims after affirmance
Paragraph IV risk	Novel’s challenge failed on the appealed obviousness issue
Generic launch risk	Delayed or materially constrained during the patent term
Label carve-out risk	Significant because the patent covered the principal colon-cleansing use
Formulation substitution risk	Possible only if a competing product avoided the asserted claim limitations
Biosimilar risk	Not applicable; SUPREP is a small-molecule drug
Settlement risk	Not resolved by the Federal Circuit opinion itself
Manufacturing workaround	Could reduce infringement exposure if the alternative product avoided the claimed method

The ruling did not prevent all potential generic competition. A later entrant could pursue a noninfringing formulation, alter its instructions, challenge other patents, or enter after patent expiration. The decision did, however, make a direct copy of the accused SUPREP method substantially more difficult to launch.

How strong was Braintree’s patent estate after the decision?

The ’149 patent had meaningful litigation strength because the Federal Circuit upheld the nonobviousness finding despite a prior-art record containing many of the claimed ingredients and bowel-preparation concepts.

Its principal strengths were:

• A clinically specific method claim;
• Evidence of technical unpredictability;
• Safety concerns in the prior art;
• A low-volume commercial product linked to the claimed method;
• FDA-approved use aligned with the patent claims; and
• A successful defense against an ANDA Paragraph IV challenge.

Its limitations were equally important:

• The decision did not validate every possible claim covering sulfate bowel preparations;
• The patent was time-limited;
• The patent’s protection depended on the claimed dosing and use conditions;
• Competitors could pursue alternative compositions or regimens; and
• Patent strength did not eliminate post-expiration generic substitution.

The case is therefore stronger as a method-of-use validity precedent than as evidence of a broad composition patent monopoly.

What licensing or settlement agreement affected the case?

The Federal Circuit opinion does not establish a licensing transaction or a final settlement agreement that resolved the dispute before judgment. The reported appellate outcome was a merits decision affirming the patent’s validity against Novel’s challenge.

No biosimilar interchangeability agreement, patent-license transfer, or cross-license was at issue in the reported decision.

What precedent did Braintree v. Novel establish for pharmaceutical patent litigation?

The case is frequently cited for the proposition that obviousness requires more than a showing that the prior art contained the individual claim elements.

Its practical lessons are:

1. A challenger must identify a reason to combine the prior-art teachings.
2. The challenger must show a reasonable expectation that the resulting pharmaceutical method would work.
3. Safety and tolerability concerns can undermine an obviousness theory.
4. Courts may give substantial weight to factual findings concerning technical motivation and clinical predictability.
5. Commercial success is relevant when connected to the claimed features.
6. ANDA litigation can preserve a method-of-use patent even when the formulation’s individual ingredients were known.

The decision also demonstrates the importance of the appellate standard of review. Obviousness is a legal conclusion based on underlying factual findings. A party seeking reversal must overcome clear-error review of findings concerning motivation, predictability, and secondary considerations.

Key Takeaways

• Braintree sued Novel after Novel filed a Paragraph IV ANDA for a generic SUPREP product.
• The dispute centered on U.S. Patent No. 6,946,149.
• The patent covered a low-volume oral sulfate colon-cleansing method.
• The district court found the asserted claims nonobvious.
• The Federal Circuit affirmed in 874 F.3d 1346.
• Prior art disclosed relevant ingredients and bowel-preparation concepts but did not establish a sufficient motivation to combine them with a reasonable expectation of success.
• Safety, electrolyte, osmolality, and tolerability concerns supported Braintree.
• The case involved a small-molecule drug, not a biologic or biosimilar.
• The decision strengthened Braintree’s position against direct generic substitution during the patent term.
• The ruling did not create a broad monopoly over all sulfate bowel-preparation products.
• No licensing or settlement agreement is identified as resolving the reported appellate dispute.

FAQs About Braintree Laboratories v. Novel Laboratories

What product was involved in Braintree Laboratories v. Novel Laboratories?

The case involved SUPREP Bowel Prep Kit, an oral sulfate solution used to cleanse the colon before colonoscopy.

What patent number was asserted against Novel Laboratories?

Braintree asserted U.S. Patent No. 6,946,149, covering an oral sulfate colon-cleansing method.

Did Novel Laboratories win its obviousness challenge?

No. The Federal Circuit affirmed the finding that the asserted claims were not proven obvious.

Was Braintree v. Novel a biosimilar patent case?

No. It was a Hatch-Waxman case involving a generic small-molecule drug product and an ANDA Paragraph IV certification.

Why was the decision important for generic drug litigation?

It confirmed that a generic challenger must prove both a reason to combine prior-art teachings and a reasonable expectation of success, particularly where the claimed pharmaceutical method presents safety and clinical predictability concerns.

References

1. Braintree Laboratories, Inc. v. Novel Laboratories, Inc., 874 F.3d 1346 (Fed. Cir. 2017).

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). SUPREP Bowel Prep Kit prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).